Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyOxaprotiline
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Oxaprotiline
- Accession Number
- DB09307
- Type
- Small Molecule
- Groups
- Experimental
- Description
Oxaprotiline is a norepinephrine reuptake inhibitor of the tetracyclic antidepressant family that is related to maprotiline. Though investigated as an antidepressant, it was never marketed. Oxaprotiline is a racemic compound composed of two isomers, R(−)- or levo- oxaprotiline (levoprotiline; CGP-12,103-A), and S(+)- or dextro- oxaprotiline (dextroprotiline; CGP-12,104-A). Both enantiomers are active, with the levo- form acting merely as an antihistamine and the dextro- form having a more expansive pharmacology, but with both unexpectedly still retaining antidepressant effects.
- Synonyms
- Hydroxymaprotiline
- Categories
- UNII
- 3V3Z2HK4LS
- CAS number
- 56433-44-4
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
Investigated for the treatment of depression.
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Acarbose Oxaprotiline may decrease the hypoglycemic activities of Acarbose. Approved, Investigational Agmatine The risk or severity of hypertension can be increased when Oxaprotiline is combined with Agmatine. Experimental, Investigational Amikacin The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Amikacin. Approved, Investigational, Vet Approved Benzphetamine Oxaprotiline may increase the vasopressor activities of Benzphetamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Oxaprotiline. Approved Botulinum Toxin Type B The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Botulinum Toxin Type B. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Oxaprotiline. Approved Bupropion The risk or severity of adverse effects can be increased when Bupropion is combined with Oxaprotiline. Approved Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxaprotiline. Approved, Investigational Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Oxaprotiline. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxaprotiline. Approved Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Oxaprotiline. Approved, Investigational Clindamycin The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Clindamycin. Approved, Vet Approved Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Oxaprotiline. Approved, Illicit Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxaprotiline. Approved Cyclosporine The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Cyclosporine. Approved, Investigational, Vet Approved Dapagliflozin Oxaprotiline may decrease the hypoglycemic activities of Dapagliflozin. Approved Desmopressin The risk or severity of hyponatremia and water intoxication can be increased when Oxaprotiline is combined with Desmopressin. Approved Desvenlafaxine The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Desvenlafaxine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxaprotiline. Approved Dexmethylphenidate The serum concentration of Oxaprotiline can be increased when it is combined with Dexmethylphenidate. Approved, Investigational Diethylpropion Oxaprotiline may increase the stimulatory activities of Diethylpropion. Approved, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Oxaprotiline. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxaprotiline. Approved, Investigational Dotarizine The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Dotarizine. Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxaprotiline. Approved, Vet Approved Eperisone The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Eperisone. Approved, Investigational Ethanol Oxaprotiline may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxaprotiline. Approved Etomidate The risk or severity of hypertension can be increased when Oxaprotiline is combined with Etomidate. Approved Fentanyl The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Oxaprotiline. Approved, Illicit, Investigational, Vet Approved Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Oxaprotiline. Approved Fluoxetine The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Fluoxetine. Approved, Vet Approved Fluspirilene The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Oxaprotiline. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Oxaprotiline. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Oxaprotiline. Approved, Investigational Glimepiride Oxaprotiline may decrease the hypoglycemic activities of Glimepiride. Approved Glipizide Oxaprotiline may decrease the hypoglycemic activities of Glipizide. Approved, Investigational Glyburide Oxaprotiline may decrease the hypoglycemic activities of Glyburide. Approved Guanfacine The risk or severity of hypertension can be increased when Oxaprotiline is combined with Guanfacine. Approved, Investigational Hydrocodone Oxaprotiline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxaprotiline. Approved Insulin Glargine Oxaprotiline may decrease the hypoglycemic activities of Insulin Glargine. Approved Insulin Human Oxaprotiline may decrease the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Lispro Oxaprotiline may decrease the hypoglycemic activities of Insulin Lispro. Approved Isocarboxazid The therapeutic efficacy of Oxaprotiline can be increased when used in combination with Isocarboxazid. Approved Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxaprotiline. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Oxaprotiline. Approved, Investigational Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with Oxaprotiline. Approved Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Oxaprotiline. Approved, Investigational Magnesium carbonate The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Magnesium carbonate. Approved, Investigational Magnesium citrate The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Magnesium citrate. Approved Magnesium hydroxide The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Magnesium hydroxide. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Oxaprotiline can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Magnesium Trisilicate. Approved Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Oxaprotiline. Approved Metformin Oxaprotiline may decrease the hypoglycemic activities of Metformin. Approved Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Oxaprotiline. Approved Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with Oxaprotiline. Approved, Investigational Naphazoline Oxaprotiline may increase the vasopressor activities of Naphazoline. Approved Neomycin The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Neomycin. Approved, Vet Approved Nylidrin The risk or severity of hypertension can be increased when Oxaprotiline is combined with Nylidrin. Approved Ondansetron The risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Oxaprotiline. Approved Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Oxaprotiline. Approved, Illicit, Investigational Oxymetazoline Oxaprotiline may increase the vasopressor activities of Oxymetazoline. Approved, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Oxaprotiline. Approved, Investigational, Vet Approved Paromomycin The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Paromomycin. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Paroxetine is combined with Oxaprotiline. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Penfluridol is combined with Oxaprotiline. Experimental Phenobarbital The metabolism of Oxaprotiline can be increased when combined with Phenobarbital. Approved, Investigational Phenylephrine Oxaprotiline may increase the vasopressor activities of Phenylephrine. Approved Polymyxin B Sulfate The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Polymyxin B Sulfate. Approved, Vet Approved Pramipexole Oxaprotiline may increase the sedative activities of Pramipexole. Approved, Investigational Pregabalin The therapeutic efficacy of Oxaprotiline can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxaprotiline. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Oxaprotiline. Approved, Investigational Pseudoephedrine Oxaprotiline may increase the vasopressor activities of Pseudoephedrine. Approved Pyrantel The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Pyrantel. Approved, Vet Approved Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Oxaprotiline. Approved Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Oxaprotiline. Approved Ropinirole Oxaprotiline may increase the sedative activities of Ropinirole. Approved, Investigational Rosiglitazone Oxaprotiline may decrease the hypoglycemic activities of Rosiglitazone. Approved, Investigational Salbutamol The risk or severity of hypertension can be increased when Oxaprotiline is combined with Salbutamol. Approved, Vet Approved Salmeterol The risk or severity of hypertension can be increased when Oxaprotiline is combined with Salmeterol. Approved Saxagliptin Oxaprotiline may decrease the hypoglycemic activities of Saxagliptin. Approved Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxaprotiline. Approved, Investigational Sitagliptin Oxaprotiline may decrease the hypoglycemic activities of Sitagliptin. Approved, Investigational Sodium phosphate, monobasic The risk or severity of seizure can be increased when Oxaprotiline is combined with Sodium phosphate, monobasic. Approved Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Oxaprotiline. Approved, Investigational Tetracycline The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Tetracycline. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Oxaprotiline. Investigational Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Oxaprotiline. Approved Tramadol The risk or severity of serotonin syndrome, sedation, and seizure can be increased when Oxaprotiline is combined with Tramadol. Approved, Investigational Trimethadione The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Trimethadione. Approved Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Oxaprotiline. Approved, Investigational Vancomycin The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Vancomycin. Approved Vecuronium The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Vecuronium. Approved Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxaprotiline. Approved Venlafaxine The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Venlafaxine. Approved Vinpocetine The risk or severity of adverse effects can be increased when Oxaprotiline is combined with Vinpocetine. Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Oxaprotiline. Approved Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Oxaprotiline. Approved, Investigational Zolpidem Oxaprotiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Oxaprotiline. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347910433
- Wikipedia
- Oxaprotiline
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Drug created on November 12, 2015 09:25 / Updated on August 02, 2018 06:17